GRO Biosciences Faces Strategic Uncertainty Amid Layoffs GRO Biosciences, a biotech startup from Harvard's George Church lab, has announced staff reductions while exploring strategic alternatives. Despite raising $60.3 million in 2024 for its enzyme-based gout therapy, the company has yet to begin clinical trials. This move reflects ongoing challenges in advancing its lead program, ProGly-Uricase.1